These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21666560)

  • 1. Novel therapies in non-small cell lung cancer.
    Zaba O; Grohe C; Merk J
    Minerva Chir; 2011 Jun; 66(3):235-44. PubMed ID: 21666560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy?
    Bergqvist M; Henriksson R; Brattström D
    In Vivo; 2005; 19(3):523-33. PubMed ID: 15875771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E; Herbst RS
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
    Kotteas EA; Charpidou AG; Syrigos KN
    Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.
    Berz D; Wanebo H
    J Surg Oncol; 2011 May; 103(6):574-86. PubMed ID: 21480252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapeutic targets in non-small cell lung cancer.
    Dy GK; Adjei AA
    Proc Am Thorac Soc; 2009 Apr; 6(2):218-23. PubMed ID: 19349491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies and non-small-cell lung cancer: work in progress?
    Gridelli C
    Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
    Wozniak A
    Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics and the new generation of targeted therapies for non-small cell lung cancer.
    Ramsey SD
    J Natl Cancer Inst; 2010 Mar; 102(5):287-8. PubMed ID: 20160167
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular markers for incidence, prognosis, and response to therapy.
    Tong BC; Harpole DH
    Surg Oncol Clin N Am; 2012 Jan; 21(1):161-75. PubMed ID: 22098838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapies for non-small cell lung cancer].
    Ostoros G; Kovács G; Szondy K; Döme B
    Orv Hetil; 2005 May; 146(21):1135-41. PubMed ID: 15991677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.